

ClinGen Arrhythmogenic Right Ventricular Cardiomyopathy Gene Curation Expert Panel

| Date | Your Name | Do you work for a laboratory that offers fee-for-service testing related to the work of your Expert Panel? | Have you made substantial contributions to the literature implicating a gene:disease relationship that relates to the work of your Expert Panel? | | Do you have any other existing or planned independent curation efforts that will potentially overlap with the scope of your ClinGen work? If so, please describe: | Please disclose any other relevant conflicts of interest (e.g. patents, intellectual property ownership, or paid consultancies related to any variants or genes associated with the work of your Expert Panel): |
|---------------------|--------------------------|--|--|--|---|---|
| | Open-Ended Response | Response | Response | If yes, please list the genes: | Open-Ended Response | Open-Ended Response |
| 2018-08-30 12:13:10 | Ray Hershberger | | Yes | BAG3 PSEN1 PSEN2 | We have an ongoing NHLBI/NHGRI funded DCM study in progress (DCM Precision Medicine study) with activities that preceded the CLINGEN work, where we adjudicate variants and have selected genes (in 2014) for this study. There is a bit of overlap, although we have leveraged ClinGen processes and cite ClinGen papers. I don't think there will be actual conflicts, but Ana Morales and I are aware of potential issues. | none. |
| 2018-08-30 8:40:22 | Courtney Thaxton | No | No | | | |
| 2018-07-24 7:56:45 | Peter van Tintelen | No | Yes | DES, PLN, | | none |
| 2018-05-02 23:42:49 | Babken Asatryan | No | No | | no | n.a. |
| 2018-05-14 22:07:41 | Ronald Lekanne Deprez | Yes | No | | no | no |
| 2018-05-14 5:49:36 | Alexandros Protonotarios | No | No | | | |
| 2018-05-11 13:29:59 | Ana | No | No | | no | none |
| 2018-05-11 12:44:45 | Elizabeth Jordan | No | No | | | |
| 2018-05-11 12:39:24 | Daniel Judge | No | Yes | Published manuscripts on mutations in these genes causing ARVC/ACM: DSG2, SCN5A. | No | Not related to this work: I have received payment as a scientific advisor to Alnylam, GSK, and Pfizer for treatments of TTR amyloidosis. |
| 2018-05-11 6:05:21 | Petros Syrris | No | Yes | DSP, JUP, DSG2, DSC2, PKP2, LMNA | NO | NONE |
| 2018-04-13 6:11:05 | Brittney Murray | No | Yes | Involved in a manuscript describing SCN5A in ARVC | No | |
| 2018-04-12 7:40:18 | Rudy Celeghin | No | No | | | |
| 2018-04-12 6:16:45 | Paul A. van der Zwaag | No | Yes | PLN (my self) DES, SCN5A (my direct colleagues) | No | |
| 2018-04-10 2:42:45 | J.D.H. Jongbloed | Yes | Yes | PLN, DES, SCN5A | no | no conflicts of interest |
| 2018-04-07 9:32:26 | Julia Cadrin-Tourigny | No | No | | | |
| 2018-04-05 5:01:33 | Argelia Medeiros Domingo | Yes | Yes | SCN5A, SCN3B, RYR2, DSC2, DSP, DSG2 | | |
| 2018-04-03 11:02:28 | Emily Brown | No | No | | Last year I was a consultant for Color Genomics for the development of their familial hypercholesterolemia panel. | I am a consultant for My Gene Counsel which is a company that writes summaries of genes and their clinical implications for physicians and patients. |
| 2018-04-01 20:56:28 | Kalliopi Pilichou | No | Yes | DSG2 | no | none |
| 2018-03-29 8:09:30 | Kathleen Wallace | No | No | | No | No COI to disclose |
| 2018-03-29 7:59:46 | Jen McLaughon | No | No | | No | |

| | | | | | | |
|---------------------|-------------|----|-----|---|---|--|
| 2018-03-28 13:44:46 | Cindy James | No | Yes | SCN5A, DSG2 Have also published large cohort studies reporting frequencies of variants in a variety of genes. | Not as such, however we are performing variant adjudication in house as part of manuscript preparation. Probably the most relevant manuscript being prepared relates to frequency of de novo desmosomal variants. | |
|---------------------|-------------|----|-----|---|---|--|